Tags

Type your tag names separated by a space and hit enter

Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia.
Am J Ther. 2010 Nov-Dec; 17(6):577-85.AJ

Abstract

These retrospective analyses of daily mean pain scores from nine placebo-controlled trials of pregabalin at 150, 300, or 600 mg/day (pregabalin, n = 1205; placebo, n = 772) examined time to significant reduction of pain during the first 2 weeks of treatment of painful diabetic peripheral neuropathy and postherpetic neuralgia. Time to onset of reduction in pain-defined as the first day for which patients treated with pregabalin had significant reductions (P < 0.05) in mean pain score compared with the placebo group for that day and the subsequent day-was calculated for all treatment groups demonstrating statistically significant reduction in pain at trial end point. The time to a 1-point or greater improvement in mean pain score was measured for each patient who was a responder at end point (30% or greater improvement in mean pain score). In seven of the nine trials (representing 11 of 14 pregabalin arms), significant reduction in pain was achieved at end point. The time to onset for reduction in pain was treatment Day 1 or 2 in nine of these successful treatment arms. Individual responder analysis confirmed that responders in the pregabalin groups reported a 1-point or greater pain reduction earlier than responders in placebo groups (P < 0.0001). However, this analysis is not a direct estimate of the likelihood that an individual patient would experience noticeable pain relief by the end of the second day. Overall, for patients who will respond to pregabalin, statistically significant and sustained reduction of pain associated with diabetic peripheral neuropathy and posttherapeutic neuralgia occurs early, usually by the end of 2 days of pregabalin treatment.

Authors+Show Affiliations

Pfizer Global Research & Development, New London, CT, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20393345

Citation

Sharma, Uma, et al. "Time to Onset of Neuropathic Pain Reduction: a Retrospective Analysis of Data From Nine Controlled Trials of Pregabalin for Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia." American Journal of Therapeutics, vol. 17, no. 6, 2010, pp. 577-85.
Sharma U, Griesing T, Emir B, et al. Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther. 2010;17(6):577-85.
Sharma, U., Griesing, T., Emir, B., & Young, J. P. (2010). Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. American Journal of Therapeutics, 17(6), 577-85. https://doi.org/10.1097/MJT.0b013e3181d5e4f3
Sharma U, et al. Time to Onset of Neuropathic Pain Reduction: a Retrospective Analysis of Data From Nine Controlled Trials of Pregabalin for Painful Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Am J Ther. 2010 Nov-Dec;17(6):577-85. PubMed PMID: 20393345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Time to onset of neuropathic pain reduction: A retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. AU - Sharma,Uma, AU - Griesing,Teresa, AU - Emir,Birol, AU - Young,James P,Jr PY - 2010/4/16/entrez PY - 2010/4/16/pubmed PY - 2011/3/2/medline SP - 577 EP - 85 JF - American journal of therapeutics JO - Am J Ther VL - 17 IS - 6 N2 - These retrospective analyses of daily mean pain scores from nine placebo-controlled trials of pregabalin at 150, 300, or 600 mg/day (pregabalin, n = 1205; placebo, n = 772) examined time to significant reduction of pain during the first 2 weeks of treatment of painful diabetic peripheral neuropathy and postherpetic neuralgia. Time to onset of reduction in pain-defined as the first day for which patients treated with pregabalin had significant reductions (P < 0.05) in mean pain score compared with the placebo group for that day and the subsequent day-was calculated for all treatment groups demonstrating statistically significant reduction in pain at trial end point. The time to a 1-point or greater improvement in mean pain score was measured for each patient who was a responder at end point (30% or greater improvement in mean pain score). In seven of the nine trials (representing 11 of 14 pregabalin arms), significant reduction in pain was achieved at end point. The time to onset for reduction in pain was treatment Day 1 or 2 in nine of these successful treatment arms. Individual responder analysis confirmed that responders in the pregabalin groups reported a 1-point or greater pain reduction earlier than responders in placebo groups (P < 0.0001). However, this analysis is not a direct estimate of the likelihood that an individual patient would experience noticeable pain relief by the end of the second day. Overall, for patients who will respond to pregabalin, statistically significant and sustained reduction of pain associated with diabetic peripheral neuropathy and posttherapeutic neuralgia occurs early, usually by the end of 2 days of pregabalin treatment. SN - 1536-3686 UR - https://www.unboundmedicine.com/medline/citation/20393345/Time_to_onset_of_neuropathic_pain_reduction:_A_retrospective_analysis_of_data_from_nine_controlled_trials_of_pregabalin_for_painful_diabetic_peripheral_neuropathy_and_postherpetic_neuralgia_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=20393345.ui DB - PRIME DP - Unbound Medicine ER -